Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
10.50
-0.42 (-3.85%)
At close: Jul 17, 2026, 4:00 PM EDT
10.71
+0.21 (2.00%)
After-hours: Jul 17, 2026, 5:09 PM EDT
Silence Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Silence Therapeutics stock has a consensus rating of "Buy" and an average price target of $29.17. The average 1-year stock price forecast is 177.81% higher than the current stock price, while the lowest is $4.00 (-61.90%) and the highest is $75 (+614.29%).
Price Target: $29.17 (+177.81%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Jun 17, 2026.
Analyst Ratings
The average analyst rating for Silence Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 6 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jun 24, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $75 | Buy | Reiterates | $75 | +614.29% | Jun 17, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $25 | Buy | Reiterates | $25 | +138.10% | Jun 12, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 11, 2026 |
| Chardan Capital | Chardan Capital | Buy Maintains $35 → $27 | Buy | Maintains | $35 → $27 | +157.14% | May 8, 2026 |
Financial Forecast
Revenue This Year
3.33M
from 559.00K
Increased by 496.51%
Revenue Next Year
4.60M
from 3.33M
Increased by 37.88%
EPS This Year
-0.37
EPS Next Year
4.79
from -0.37
EPS and Forward PE are based on non-GAAP adjusted numbers.